NCX 4040

Drug Profile

NCX 4040

Latest Information Update: 16 May 2007

Price : $50

At a glance

  • Originator NicOx
  • Class Antineoplastics; Nitro compounds; Salicylic acids
  • Mechanism of Action Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Colorectal cancer

Most Recent Events

  • 18 Oct 2004 Data presented at the 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2004) have been added to the pharmacokinetics and Cancer pharmacodynamics section ,
  • 15 Oct 2004 Preclinical trials in Colorectal cancer in Italy (PO)
  • 25 Mar 2003 Preclinical trials in Colorectal cancer in France (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top